Literature DB >> 18456348

Gastric emptying in response to IAPP and CCK in rats with subdiaphragmatic afferent vagotomy.

Johan Wickbom1, Margery K Herrington, Johan Permert, Anders Jansson, Urban Arnelo.   

Abstract

In the subdiaphragmatic vagal deafferentation procedure (SDA), the afferent fibers of the vagus are surgically severed unilaterally where they enter the brain stem. The technique includes a subdiaphragmal truncal vagotomy performed on the contralateral side. This procedure has been used to study the control of food intake, but it has not been used previously to investigate the role of vagal afferent fibers in the control of gastric emptying (GE). The current experiment studied the effect of SDA on the inhibition of GE by islet amyloid polypeptide (IAPP or amylin) and cholecystokinin (CCK) in awake, unrestrained rats with gastric cannulas. The experimental group underwent subdiaphragmatic vagal deafferentation; the control group had sham operations. All rats received 20-min intravenous infusions of IAPP (1, 3, 9, 27, and 81 pmol/kg/min), CCK (3, 30 and 90 pmol/kg/min), and normal saline in random order. Gastric emptying of saline was measured by the phenol red method during the last 5 min of each infusion period. CCK dose-dependently inhibited gastric emptying in both the control and SDA animals. The inhibition of GE by CCK was significantly attenuated by SDA (p<0.01). IAPP also inhibited gastric emptying dose-dependently, but the difference between the SDA and control groups was not significant. The current experiment, which used a different methodology than previous studies, provides support for the hypothesis that the inhibition of gastric emptying by CCK, but not by IAPP, is mediated partly by afferent vagal fibers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18456348     DOI: 10.1016/j.regpep.2008.03.010

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  10 in total

Review 1.  Regulation of energy balance by a gut-brain axis and involvement of the gut microbiota.

Authors:  Paige V Bauer; Sophie C Hamr; Frank A Duca
Journal:  Cell Mol Life Sci       Date:  2015-11-05       Impact factor: 9.261

2.  Time-course of recovery of gastric emptying and motility in rats with experimental spinal cord injury.

Authors:  E Qualls-Creekmore; M Tong; G M Holmes
Journal:  Neurogastroenterol Motil       Date:  2009-06-30       Impact factor: 3.598

Review 3.  GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities.

Authors:  Jonathan D Roth; Mary R Erickson; Steve Chen; David G Parkes
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 4.  Amylin-mediated control of glycemia, energy balance, and cognition.

Authors:  Elizabeth G Mietlicki-Baase
Journal:  Physiol Behav       Date:  2016-02-27

Review 5.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

Review 6.  Control of energy homeostasis by amylin.

Authors:  Thomas A Lutz
Journal:  Cell Mol Life Sci       Date:  2011-12-23       Impact factor: 9.261

Review 7.  Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure.

Authors:  T A Lutz
Journal:  Int J Obes Suppl       Date:  2016-11-16

Review 8.  Amylin at the interface between metabolic and neurodegenerative disorders.

Authors:  Thomas A Lutz; Urs Meyer
Journal:  Front Neurosci       Date:  2015-06-16       Impact factor: 4.677

9.  Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?

Authors:  Wei Qiao Qiu; Haihao Zhu
Journal:  Front Aging Neurosci       Date:  2014-07-29       Impact factor: 5.750

Review 10.  Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases.

Authors:  Nina Sonne; Morten A Karsdal; Kim Henriksen
Journal:  Mol Metab       Date:  2020-11-07       Impact factor: 7.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.